Drug Profile
PTG 100
Alternative Names: PTG-100Latest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Protagonist Therapeutics
- Class Anti-inflammatories; Antiulcers; Disulfides; Peptides
- Mechanism of Action Alpha4beta7 integrin antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Coeliac disease
- Discontinued Inflammatory bowel diseases; Ulcerative colitis
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for phase-I development in Coeliac disease in USA (PO, Capsule)
- 03 Apr 2022 Protagonist Therapeutics and Stanford University complete a phase I trial in Coeliac disease in USA (PO, Capsule) (NCT04524221)
- 26 Feb 2021 Phase-I clinical trials in Coeliac disease in USA (PO) (PTG-100-05-CeD)